Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

BCAT1 Antikörper

BCAT1 Reaktivität: Human, Maus, Hund WB, IHC Wirt: Maus Monoclonal 3F5 unconjugated
Produktnummer ABIN2716546
  • Target Alle BCAT1 Antikörper anzeigen
    BCAT1 (Branched Chain Amino-Acid Transaminase 1, Cytosolic (BCAT1))
    Reaktivität
    • 45
    • 24
    • 20
    • 5
    • 4
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    Human, Maus, Hund
    Wirt
    • 61
    • 6
    Maus
    Klonalität
    • 63
    • 4
    Monoklonal
    Konjugat
    • 30
    • 5
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser BCAT1 Antikörper ist unkonjugiert
    Applikation
    • 50
    • 29
    • 23
    • 14
    • 13
    • 13
    • 9
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC)
    Produktmerkmale
    Homo sapiens branched chain amino-acid transaminase 1, cytosolic (BCAT1), transcript variant 1
    Aufreinigung
    Purified from mouse ascites fluids by affinity chromatography
    Immunogen
    Full length human recombinant protein of human BCAT1(NP_005495) produced in HEK293T cell.
    Klon
    3F5
    Isotyp
    IgG2a
    Top Product
    Discover our top product BCAT1 Primärantikörper
  • Applikationshinweise
    WB 1:500~2000, IHC 1:150,
    Kommentare

    The concentration of the product may vary between diferrent lots.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.5-1.0 mg/mL
    Buffer
    PBS (PH 7.3) containing 1 % BSA, 50 % glycerol and 0.02 % sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
  • Cho, Jeon, Park, Park, Kang, Choi: "BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients." in: Scientific reports, Vol. 7, Issue 1, pp. 17740, (2017) (PubMed).

    Hattori, Tsunoda, Konuma, Kobayashi, Nagy, Glushka, Tayyari, McSkimming, Kannan, Tojo, Edison, Ito: "Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia." in: Nature, Vol. 545, Issue 7655, pp. 500-504, (2017) (PubMed).

  • Target
    BCAT1 (Branched Chain Amino-Acid Transaminase 1, Cytosolic (BCAT1))
    Andere Bezeichnung
    BCAT1 (BCAT1 Produkte)
    Synonyme
    fj66g02 antikoerper, zgc:73157 antikoerper, wu:fj66g02 antikoerper, Bcatc antikoerper, BCATC antikoerper, BCT1 antikoerper, ECA39 antikoerper, MECA39 antikoerper, PNAS121 antikoerper, PP18 antikoerper, BCATc antikoerper, Eca39 antikoerper, branched chain amino-acid transaminase 1, cytosolic antikoerper, branched chain amino acid transaminase 1 antikoerper, branched chain amino-acid transaminase 1, cytosolic L homeolog antikoerper, branched chain aminotransferase 1, cytosolic antikoerper, bcat1 antikoerper, BCAT1 antikoerper, bcat1.L antikoerper, Bcat1 antikoerper
    Hintergrund
    This gene encodes the cytosolic form of the enzyme branched-chain amino acid transaminase. This enzyme catalyzes the reversible transamination of branched-chain alpha-keto acids to branched-chain L-amino acids essential for cell growth. Two different clinical disorders have been attributed to a defect of branched-chain amino acid transamination: hypervalinemia and hyperleucine-isoleucinemia. As there is also a gene encoding a mitochondrial form of this enzyme, mutations in either gene may contribute to these disorders. Alternatively spliced transcript variants have been described.
    Molekulargewicht
    42.8 kDa
    Gen-ID
    586
    NCBI Accession
    NM_005504
    HGNC
    586
Sie sind hier:
Kundenservice